June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Uptake and Release of ciprofloxacin and dexamethasone from commercial contact lens materials
Author Affiliations & Notes
  • Alex Hui
    School of Optometry and Vision Science, University of Waterloo, Waterloo, ON, Canada
    Centre for Contact Lens Research, University of Waterloo, Waterloo, ON, Canada
  • Lyndon Jones
    School of Optometry and Vision Science, University of Waterloo, Waterloo, ON, Canada
    Centre for Contact Lens Research, University of Waterloo, Waterloo, ON, Canada
  • Footnotes
    Commercial Relationships Alex Hui, None; Lyndon Jones, Alcon (F), Alcon (R), Allergan (F), Abbott Medical Optics (R), Bausch & Lomb (R), Ciba Vision (F), Ciba Vision (R), CooperVision (F), Johnson & Johnson (F), Johnson & Johnson (R)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1086. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alex Hui, Lyndon Jones; Uptake and Release of ciprofloxacin and dexamethasone from commercial contact lens materials. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1086.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To investigate the uptake and release of a novel antibiotic-steroid solution from three commercial contact lenses.

Methods: A 0.3% ciprofloxacin (CF) and 0.1% dexamethasone-23-phosphate (DXP) solution was prepared in acetate buffer using cyclodextrins to prevent precipitation. Linear standard curves were used to quantify the concentration of the two species simultaneously using a combination of fluorescence spectrophotometry, which is specific to the CF species (excitation at 274 nm, emission at 419 nm), and UV absorbance, which can be used to quantify the DXP in solution (absorbance at 241 nm). Three commercially available contact lenses, balafilcon A (Purevision2, Bausch+Lomb), etafilcon A (1-Day Acuvue Moist, Vistakon) and lotrafilcon B (Air Optix, Alcon Vision Care) were placed in 2 mL of the CF-DXP solution and soaked at room temperature for 24 hours. The lenses were then removed and placed in 2 mL of phosphate buffered saline, and the release of CF and DXP into solution was monitored over 24 hours. Statistical analysis was performed using a repeated measures ANOVA.

Results: All lens types were able to release significant amounts of CF and DXP (p<0.05). In agreement with previous studies, the etafilcon A material released the largest amount of CF (p<0.05 when compared to other lens types), while the balafilcon A material released the most DXP but this effect was not statistically significant (p>0.05). The absolute amount of CF and DXP released was less than when the species were loaded into the lenses individually compared to previous studies, suggesting a possible interaction effect. The majority of the drug was released within the first three hours, suggesting that specifically tailored and designed lenses are needed if these drug delivery lenses are to be useful.

Conclusions: Antibiotic steroid combination drops are one of the most commonly prescribed agents in the ophthalmic industry, thus they are a natural target for those interested in developing contact lens drug delivery devices. Further study is required to tailor the release rates and amounts to be clinically relevant.

Keywords: 477 contact lens • 557 inflammation • 422 antibiotics/antifungals/antiparasitics  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×